相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2022)
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Michael A. Vogelbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
Naoyuki Nogami et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis
Yin Yang et al.
CLINICAL LUNG CANCER (2022)
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer
Joshua K. Sabari et al.
CLINICAL CANCER RESEARCH (2022)
Brain Metastases in EGFR- and ALK-Positive NSCLC : Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation
Nicholas J. Thomas et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
Bob T. Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases
Richard S. P. Huang et al.
ONCOLOGIST (2022)
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
Yosuke Kawashima et al.
LANCET RESPIRATORY MEDICINE (2022)
Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases
Guanqun Yang et al.
FRONTIERS IN IMMUNOLOGY (2022)
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis
Jonathan T. Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Genomic profiling and molecular targeting of lung cancer brain metastases
H. Cheng et al.
ANNALS OF ONCOLOGY (2022)
Clinical trial of proton craniospinal irradiation for leptomeningeal metastases
T. Jonathan Yang et al.
NEURO-ONCOLOGY (2021)
Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy
Lova Sun et al.
CLINICAL LUNG CANCER (2021)
Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial
Zhi-qin Lu et al.
THORACIC CANCER (2021)
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
E. Felip et al.
ANNALS OF ONCOLOGY (2021)
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al.
LANCET (2021)
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J. Riely et al.
CANCER DISCOVERY (2021)
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
Tianqing Chu et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Cephalomannine inhibits hypoxia-induced cellular function via the suppression of APEX1/HIF-1α interaction in lung cancer
Asmat Ullah et al.
CELL DEATH & DISEASE (2021)
Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
Vivek Subbiah et al.
CLINICAL CANCER RESEARCH (2021)
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer
Jordi Remon et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021,-189, and-407
Steven F. Powell et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Justin F. Gainor et al.
LANCET ONCOLOGY (2021)
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
Jarushka Naidoo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Immunotherapy and radiation for high-grade glioma: a narrative review
Kareem R. Fakhoury et al.
TRANSLATIONAL CANCER RESEARCH (2021)
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
Paul D. Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation?Positive Non?Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
James C. H. Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells
Florian Klemm et al.
CELL (2020)
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Shirish Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2020)
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K. Brastianos et al.
NATURE MEDICINE (2020)
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases
Lu Dai et al.
ANNALS OF PALLIATIVE MEDICINE (2020)
Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
T. John et al.
ANNALS OF ONCOLOGY (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors
Lori A. Ramkissoon et al.
FRONTIERS IN NEUROLOGY (2020)
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Central Nervous System Cancers Version 3.2020
Louis Burt Nabors et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data
Eric J. Lehrer et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer
Mihong Choi et al.
CLINICAL LUNG CANCER (2019)
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC
Mei-Mei Zheng et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
Lizza E. L. Hendriks et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Atezolizumab in patients with advanced non -small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
Shirish M. Gadgeel et al.
LUNG CANCER (2019)
Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications
Adrienne Boire et al.
NEURO-ONCOLOGY (2019)
Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study
Birgitte Bjornhart et al.
ACTA ONCOLOGICA (2019)
Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.
Alexander E. Drilon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
Alessandro Leonetti et al.
DRUG RESISTANCE UPDATES (2019)
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2019)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa et al.
LANCET ONCOLOGY (2019)
How we treat patients with leptomeningeal metastases
Emilie Le Rhun et al.
ESMO OPEN (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
Y. S. Li et al.
ANNALS OF ONCOLOGY (2018)
Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment
Elie El Rassy et al.
CANCER TREATMENT REVIEWS (2018)
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients
Arthur Geraud et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Leptomeningeal metastases in non-small-cell lung cancer
Haiying Cheng et al.
LANCET ONCOLOGY (2018)
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
Makoto Nishio et al.
LUNG CANCER (2018)
Combining Immunotherapy and Radiotherapy for Cancer Treatment Current Challenges and Future Directions
Yifan Wang et al.
FRONTIERS IN PHARMACOLOGY (2018)
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK plus ) non-small-cell lung cancer: CNS efficacy results from the ALEX study
S. Gadgeel et al.
ANNALS OF ONCOLOGY (2018)
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
Thanyanan Reungwetwattana et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J. Solomon et al.
LANCET ONCOLOGY (2018)
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naive Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis
William J. Magnuson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis
Dianhe Li et al.
JOURNAL OF THORACIC DISEASE (2017)
Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells
Ben-Yuan Jiang et al.
CLINICAL CANCER RESEARCH (2017)
Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era
J. Remon et al.
CANCER TREATMENT REVIEWS (2017)
The movers and shapers in immune privilege of the CNS
Britta Engelhardt et al.
NATURE IMMUNOLOGY (2017)
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases
Anna S. Berghoff et al.
ONCOIMMUNOLOGY (2016)
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
A. S. Mansfield et al.
ANNALS OF ONCOLOGY (2016)
Single-Fraction Versus Multifraction (3 x 9 Gy) Stereotactic Radiosurgery for Large ( > 2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis
Giuseppe Minniti et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases A Randomized Clinical Trial
Paul D. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis
Kimberly L. Johung et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study
Sai-Hong Ignatius Ou et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Yang-Si Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib
Justin F. Gainor et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
Paula Mulvenna et al.
LANCET (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis
Ya-Lan Wu et al.
ONCOLOGY LETTERS (2016)
Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
Justin F. Gainor et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
Isabella Zhang et al.
LANCET ONCOLOGY (2015)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James C-H Yang et al.
LANCET ONCOLOGY (2015)
CellSearch® technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis
Qian Tu et al.
LUNG CANCER (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
Leticia De Mattos-Arruda et al.
NATURE COMMUNICATIONS (2015)
Role of Local Radiation Therapy in Cancer Immunotherapy
Sandra Demaria et al.
JAMA ONCOLOGY (2015)
EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
Dong-Yeop Shin et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study
Masaaki Yamamoto et al.
LANCET ONCOLOGY (2014)
Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases
A. Ali et al.
CURRENT ONCOLOGY (2013)
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer
Andrew J. Weickhardt et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment
Agnes V. Tallet et al.
RADIATION ONCOLOGY (2012)
RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF BEVACIZUMAB THERAPY FOR RADIATION NECROSIS OF THE CENTRAL NERVOUS SYSTEM
Victor A. Levin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial
Eric L. Chang et al.
LANCET ONCOLOGY (2009)
The biology of metastasis to a sanctuary site
Diane Palmieri et al.
CLINICAL CANCER RESEARCH (2007)
Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system
JS Barnholtz-Sloan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)